Investors
Learn more about how we deliver for patients and shareholders in a way that embodies our values.
Financial reportings
Events and presentations
Press releases
Our pipeline
NYSE : BMY
- Volume
- Open
Stock represented on a 20-minute delay.
Facts at a glance*
$48.2B
Total revenue$14.2B
Cash flow fromoperating activities
$5.0B
Cash returned to shareholders194
Years of consecutive dividend payments55%
Percent of revenue attributable to Growth Portfolio$10.0B
Invested in R&D>1B: 7
Growth portfolio assets annualizing over $1B in revenue15+
New medicines in registrational trials2Therapeutic areas of focus
Oncology
Hematology
Neuroscience
Immunology
Cardiovascular
* Source: Data based on full-year 2025 business results unless otherwise noted. 1Represents cash returned through the dividend; 2As of 3/31/26.
Reports
AS OF APRIL 30, 2026
- 50 Compounds in development
- 40+ Disease areas being studied
Our pipeline targets areas where we can deliver transformative medicines — for patients who need them most.
Investor resources
BMY Shareholders' FAQs
Frequently asked questions about Bristol Myers Squibb sharesCelgene shareholders' FAQs
Read acquisition FAQs for Celgene shareholdersMirati shareholders' FAQs
Read FAQs for Mirati shareholdersAbraxane CVR notification
Bristol-Myers Squibb Company Update on Abraxane CVR PaymentSubscribe to alerts
Stay informed with timely updates. Sign up to receive the latest investor news delivered to your inbox.